14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis
Key Takeaways
Estrogen stimulates hepatic thyroxine-binding globulin (TBG) synthesis, expanding the circulating total T4 and T3 pool, while first-trimester hCG shares structural alpha-subunit homology with TSH, exerting weak agonism that physiologically suppresses serum TSH during weeks 8–14.
Primary hypothyroidism is predominantly caused by Hashimoto thyroiditis (positive anti-TPO antibodies); clinical sequelae in women include menorrhagia, anovulatory infertility, and galactorrhea/amenorrhea triggered by elevated hypothalamic TRH stimulating pituitary lactotrophs.
Levothyroxine (full replacement ~1.6 mcg/kg/day) must be taken on an empty stomach with water 30–60 minutes before breakfast, separated from calcium, iron, and prenatal vitamins by at least 4 hours, with TSH monitored every 6–8 weeks during dose titration.
Maternal thyroid hormone is indispensable for first-trimester fetal neurocognitive development; women with pre-existing hypothyroidism must preemptively increase levothyroxine dosage by 20%–30% (two additional doses weekly) immediately upon a missed period or positive pregnancy test, targeting the lower half of the trimester-specific TSH range (or <2.5 mIU/L when no local range exists; ATA 2017).
Hyperthyroidism in pregnancy requires propylthiouracil (PTU) in the first trimester to avoid methimazole embryopathy (aplasia cutis congenita, choanal atresia), with many clinicians switching to methimazole after the first trimester to limit PTU hepatotoxicity; postpartum thyroiditis is a destructive, biphasic process (hyperthyroid followed by hypothyroid) where thionamides are ineffective.
Thyroid Physiology Across the Female Lifespan & Pregnancy
Thyroid homeostasis is intimately linked to female reproductive endocrinology. Estrogen, human chorionic gonadotropin (hCG), and gestational hemodynamics produce profound endocrine adaptations:
1. Estrogen & Thyroxine-Binding Globulin (TBG)
Circulating estrogen—whether endogenous during pregnancy or exogenous via oral contraceptives or menopausal hormone therapy—stimulates hepatic TBG synthesis and slows TBG clearance through sialylation. Serum TBG concentrations double within weeks of estrogen exposure. As TBG binds circulating free thyroxine (T4) and triiodothyronine (T3), the hypothalamic-pituitary-thyroid (HPT) axis increases hormone synthesis until binding sites saturate and free hormone levels normalize. Consequently, total T4 and total T3 concentrations increase by roughly 50%, whereas free T4 (FT4) and free T3 (FT3) remain normal in euthyroid women. Total hormone measurements cannot be used to assess thyroid status in hyperestrogenic states.
2. Human Chorionic Gonadotropin (hCG) Cross-Reactivity
hCG shares an identical 92-amino acid α-subunit with TSH, LH, and FSH, with homology in its β-subunit. At peak concentrations between 8 and 14 weeks, circulating hCG binds to and weakly stimulates the thyroidal TSH receptor. This stimulates thyroid hormone secretion, which exerts negative feedback on pituitary thyrotrophs, producing a physiologic suppression of serum TSH (often dropping <0.4 mIU/L or <0.1 mIU/L in up to 15% of normal pregnancies, particularly in multifetal gestations or hyperemesis gravidarum).
3. Renal Iodine Clearance & Gestational Demands
During pregnancy, marked renal hyperfiltration increases urinary iodide excretion, while the feto-placental unit actively extracts maternal iodide. The WHO and American Thyroid Association (ATA) recommend that pregnant and lactating women ingest 250 mcg of elemental iodine daily, typically achieved with prenatal vitamins containing 150 mcg of potassium iodide.
Primary Hypothyroidism & Hashimoto Thyroiditis
Primary hypothyroidism occurs when intrinsic thyroid pathology impairs hormone synthesis, driving compensatory pituitary TSH hypersecretion.
Etiology & Pathogenesis
- Hashimoto Thyroiditis (Chronic Autoimmune Lymphocytic Thyroiditis): The predominant etiology in iodine-sufficient regions. Pathophysiologically characterized by cell-mediated destruction: CD4+ and CD8+ T lymphocytes infiltrate thyroid follicles, accompanied by oxyphilic (Hürthle) cell metaplasia, follicular atrophy, and interstitial fibrosis.
- Serologic Biomarkers: Serum anti-thyroid peroxidase (anti-TPO) antibodies are positive in >90% to 95% of patients; anti-thyroglobulin (anti-Tg) antibodies are present in 60% to 80%.
Clinical Manifestations & Gynecologic Sequelae
Systemic features reflect metabolic slowing: fatigue, cold intolerance, weight gain, constipation, dry skin, diffuse alopecia, periorbital myxedema, hoarseness, carpal tunnel syndrome, and delayed relaxation ("hung-up") deep tendon reflexes.
- Menstrual Dysfunction: Causes menorrhagia (heavy menstrual bleeding) early in the course due to impaired estrogen clearance and clotting factor deficits, progressing to oligomenorrhea or secondary amenorrhea as anovulation develops.
- TRH-Mediated Hyperprolactinemia: The hypothalamus hypersecretes Thyrotropin-Releasing Hormone (TRH) to stimulate the failing thyroid. TRH directly stimulates pituitary lactotrophs, causing hyperprolactinemia, galactorrhea, and hypogonadotropic anovulatory subfertility.
Diagnostic Laboratory Profiles
- Primary Overt Hypothyroidism: Elevated serum TSH (>4.0–4.5 mIU/L) accompanied by low free T4 (<0.8 ng/dL).
- Subclinical Hypothyroidism: Elevated serum TSH (>4.0–4.5 mIU/L) with a normal free T4 concentration. Progression to overt failure occurs at ~5% annually, accelerated by positive anti-TPO titers.
Pharmacotherapy: Levothyroxine Management
Synthetic levothyroxine (LT4) is the first-line therapy of choice for hypothyroidism.
Dosing Principles & Absorption Rules
- Full Replacement Dose: Approximately 1.6 mcg/kg/day based on ideal body weight for young, healthy non-pregnant adults without comorbidities (typically 75 to 125 mcg daily).
- Elderly Patients & Coronary Artery Disease: Initiate cautiously at 25 to 50 mcg daily and titrate slowly by 12.5 to 25 mcg increments every 6 to 8 weeks to avoid cardiac ischemia or tachyarrhythmias.
- Fasting Requirement: Take once daily with water on an empty stomach, strictly 30 to 60 minutes before breakfast, or at bedtime 3 to 4 hours after the last meal.
- The 4-Hour Separation Rule: Polyvalent cations and acid suppressors dramatically reduce levothyroxine bioavailability. Separate levothyroxine administration by at least 4 hours from calcium carbonate, ferrous sulfate (iron), prenatal vitamins, aluminum/magnesium antacids, sucralfate, and bile acid sequestrants.
Monitoring & Titration
Because levothyroxine has a ~7-day half-life, steady-state concentrations require 4 to 6 weeks. Recheck serum TSH 6 to 8 weeks after initiating therapy or adjusting the dose. Once stable, monitor TSH annually.
Hypothyroidism in Pregnancy: Maternal-Fetal Safeguards
During the first 10 to 12 weeks of gestation, the embryo relies 100% on transplacental passage of maternal T4 for cerebral cortical neurogenesis and neuronal migration.
Obstetric Risks & Trimester Targets
Untreated maternal hypothyroidism causes irreversible neurocognitive deficits (loss of offspring IQ points), congenital cretinism, spontaneous miscarriage, preeclampsia, placental abruption, and low birth weight.
- TSH Targets: The 2017 ATA guideline targets the lower half of the trimester-specific reference range in treated women, or <2.5 mIU/L when no local range is available. For diagnosing hypothyroidism without a local range, the first-trimester upper limit is about 4.0 mIU/L.
- Empirical Dose Escalation Protocol: Women with pre-existing hypothyroidism must be instructed to immediately increase their levothyroxine dose by 20% to 30% upon a missed period or positive pregnancy test. This is achieved by taking two additional tablets per week (e.g., doubling the dose on two designated days, such as Mondays and Thursdays).
- Gestational Surveillance: Order serum TSH and free T4 immediately upon pregnancy confirmation, and recheck TSH every 4 weeks throughout the first half of pregnancy.
Hyperthyroidism & Thyrotoxicosis
Etiologies & Diagnostics
- Graves Disease: Circulating thyroid-stimulating immunoglobulins (TSI) continuously activate TSH receptors. Hallmarks: diffuse toxic goiter with vascular bruit, Graves ophthalmopathy (exophthalmos, proptosis), and pretibial myxedema.
- Toxic Nodular Goiter & Subacute Thyroiditis: Autonomous nodules or post-viral inflammatory follicular destruction.
- Diagnostic Profile: Suppressed TSH (<0.1 mIU/L) with elevated free T4 and/or free T3. Radioactive Iodine Uptake (RAIU) differentiates high-uptake states (Graves) from low-uptake states (subacute/postpartum thyroiditis: uptake <1%–2%).
Pharmacotherapy: Methimazole vs. Propylthiouracil (PTU)
Thionamides inhibit thyroid peroxidase (TPO), blocking iodine organification and coupling.
| Clinical Parameter | Methimazole (MMI) | Propylthiouracil (PTU) |
|---|---|---|
| Primary Indications | Drug of choice in non-pregnant adults and 2nd/3rd trimesters of pregnancy. | Drug of choice during 1st trimester of pregnancy, and in acute thyroid storm. |
| Mechanism of Action | Inhibits TPO (iodine organification and coupling). | Inhibits TPO AND blocks peripheral conversion of T4 to T3. |
| Gestational Teratogenicity | Associated with Methimazole Embryopathy in 1st trimester: aplasia cutis congenita, choanal atresia, esophageal atresia. | Lower teratogenic potential; acceptable during embryonic organogenesis. |
| Black Box Warning & Toxicity | Agranulocytosis (fever/sore throat; check CBC stat); cholestatic jaundice. | Black Box Warning for severe, idiosyncratic fulminant hepatotoxicity / acute liver failure. |
Important
In women with Graves disease who become pregnant on methimazole, switch to PTU for the first trimester (or, if euthyroid on a low dose, consider stopping therapy with close monitoring). After the first trimester many clinicians return to methimazole to limit PTU hepatotoxicity, although the ATA notes the benefit of switching is uncertain.
Radioactive Iodine Ablation (I-131)
Radioactive iodine ablation destroys thyroid follicular cells. It is strictly contraindicated in pregnancy and lactation, as radioiodine crosses the placenta and destroys the fetal thyroid. Require a negative pregnancy test within 48 hours prior to administration and reliable contraception for at least 6 months post-treatment.
Postpartum Thyroiditis (PPT)
Postpartum thyroiditis is an autoimmune, destructive lymphocytic thyroiditis developing within the first 12 months postpartum. It occurs in roughly 5% to 10% of postpartum women, rising to 30% to 50% in women with positive anti-TPO antibodies or Type 1 diabetes.
The Triphasic Clinical Course
- Phase 1: Hyperthyroid Phase (1 to 4 Months Postpartum; Duration: 2 to 8 Weeks): Autoimmune attack lyses follicles, releasing stored hormone into circulation. Radioactive iodine uptake is suppressed (<1%–2%). Symptoms include nervousness, palpitations, and heat intolerance.
- Management: Thionamides (methimazole/PTU) are completely INEFFECTIVE because there is no excess hormone synthesis. Treat palpitations with beta-blockers (propranolol 20–40 mg PO TID).
- Phase 2: Hypothyroid Phase (4 to 8 Months Postpartum; Duration: Several Months): Depleted follicles fail to synthesize adequate hormone, leading to fatigue, lethargy, cold intolerance, weight retention, and impaired lactation. Frequently misdiagnosed as postpartum depression (PPD); screen serum TSH in all postpartum patients presenting with mood changes or fatigue. Treat with temporary levothyroxine for 6 to 12 months if symptomatic or TSH >10 mIU/L.
- Phase 3: Recovery Phase (12 to 18 Months Postpartum): 70% to 80% experience spontaneous recovery and return to euthyroidism. However, 20% to 30% develop permanent overt hypothyroidism requiring lifelong levothyroxine, with >50% recurrence in subsequent pregnancies.
A 28-year-old female with a 4-year history of primary hypothyroidism managed with levothyroxine 88 mcg daily presents to the clinic after obtaining a positive home pregnancy test. Her last menstrual period was 5 weeks ago. She feels well and denies nausea or vaginal bleeding. Her pre-pregnancy TSH checked 3 months ago was 1.8 mIU/L. What is the most appropriate immediate clinical management plan for this patient?
Maintain her current levothyroxine dosage of 88 mcg daily and check a serum TSH at her first scheduled prenatal visit at 10 weeks gestation.
Discontinue levothyroxine immediately until fetal cardiac activity is documented on transvaginal ultrasonography.
Decrease levothyroxine to 75 mcg daily because circulating pregnancy-induced estrogen enhances thyroid hormone bioavailability.
Increase her levothyroxine by about 25%–30% now (two extra tablets weekly) and check TSH and free T4 today.
A 26-year-old female at 8 weeks gestation presents with severe palpitations, resting tremor, heat intolerance, and a 4-lb weight loss over the past 3 weeks. Physical examination reveals a resting heart rate of 116 bpm, fine bilateral hand tremor, and a diffusely enlarged, nontender thyroid gland with a faint vascular bruit. Laboratory evaluation confirms thyrotoxicosis: serum TSH is <0.01 mIU/L, free T4 is 2.8 ng/dL (elevated), and thyroid-stimulating immunoglobulin (TSI) titers are markedly elevated, establishing a diagnosis of Graves disease. Which pharmacotherapeutic strategy represents the standard of care for this patient at this gestational age?
Initiate oral methimazole 20 mg daily, as it is the most potent thionamide and carries no hepatic risks.
Start propylthiouracil (PTU) for the rest of the first trimester, then consider switching to methimazole.
Administer radioactive iodine ablation (I-131) immediately, followed by high-dose levothyroxine replacement.
Withhold antithyroid medications and manage symptoms exclusively with high-dose propranolol until after delivery.
A 31-year-old female presents to the clinic 6 months postpartum complaining of severe fatigue, uncharacteristic weight retention, cold intolerance, dry skin, and profound lack of energy. Her delivery was uncomplicated, and she is currently breastfeeding her infant. Her family and friends have suggested she has postpartum depression. Physical examination reveals dry skin, delayed deep tendon reflexes, and a resting heart rate of 54 bpm. Laboratory evaluation reveals a serum TSH of 18.2 mIU/L and a free T4 of 0.5 ng/dL (low). Serum anti-TPO antibodies are strongly positive. What is the most likely diagnosis, and what is the underlying pathophysiology and management?
Postpartum depression; initiate an SSRI such as sertraline and withhold thyroid hormone replacement.
Graves disease recurrence; initiate high-dose propylthiouracil and advise immediate cessation of breastfeeding.
Hypothyroid phase of postpartum thyroiditis; start temporary levothyroxine and reassess in 6–12 months.
Pituitary apoplexy (Sheehan syndrome); obtain emergency sellar MRI and initiate stress-dose corticosteroids.
Sections you finish are checked off in the contents.